Treatment of depression

Anew Era TMS & Psychiatry Brings TMS Therapy to Dallas, TX

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Neuroscience, Medicine, Neurotechnology, Electrotherapy, Medical devices, Neuropsychology, Treatment of depression, Transcranial magnetic stimulation, TMS, Todd M. Hutton, Non-invasive cerebellar stimulation

DALLAS, July 29, 2021 /PRNewswire-PRWeb/ --Anew Era TMS & Psychiatry, known for their locations all over Southern California, offers the highest level of psychiatric expertise available, and the new revolutionary treatment, Transcranial Magnetic Stimulation (TMS), opens a new location in Dallas, Texas.

Key Points: 
  • DALLAS, July 29, 2021 /PRNewswire-PRWeb/ --Anew Era TMS & Psychiatry, known for their locations all over Southern California, offers the highest level of psychiatric expertise available, and the new revolutionary treatment, Transcranial Magnetic Stimulation (TMS), opens a new location in Dallas, Texas.
  • Anew Era TMS & Psychiatry offers patients their very best chance for successful depressive symptomatic relief through the latest, most advanced, FDA cleared, non-medicinal treatment solution.
  • Breanna Splain, Managing Partner and Chief Strategic Officer at Anew Era TMS & Psychiatry, began as one of the first employees of Anew Era TMS & Psychiatry.
  • During a TMS Treatment, the electromagnetic currents stimulate nerve cells, activating regions of the brain that have become less active.

BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

New Study Published in Nature Journal, Translational Psychiatry, by Taliaz, Presents New Approach for Predicting Response to Depression Treatment

Retrieved on: 
Wednesday, July 21, 2021
Major depressive disorder, Health sciences, Psychiatry, Branches of biology, Psychiatric diagnosis, STAR*D, Treatment of depression, Pharmacogenomics, Antidepressant, Treatment-resistant depression

"Current practice for MDD treatment relies mainly on trial and error, with an estimated 4253% response rates for antidepressant use.

Key Points: 
  • "Current practice for MDD treatment relies mainly on trial and error, with an estimated 4253% response rates for antidepressant use.
  • The authors analyzed response patterns of more than 4500 patients to antidepressant medications in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study and the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS).
  • "This peer-reviewed publication corroborates our unique approach for the design of the PREDICTIX prediction algorithm to optimize treatment for mental health.
  • The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis.

MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Psychiatry, Neuroscience, Neurotechnology, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, Brainsway, Major depressive disorder, Obsessive–compulsive disorder

The event will feature an opportunity for local mental health providers in the Charlotte area to meet the MindPath Care Center staff and watch live demonstrations of BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) treatment offerings for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).

Key Points: 
  • The event will feature an opportunity for local mental health providers in the Charlotte area to meet the MindPath Care Center staff and watch live demonstrations of BrainsWays Deep Transcranial Magnetic Stimulation (Deep TMS) treatment offerings for major depressive disorder (MDD) and obsessive-compulsive disorder (OCD).
  • Because Deep TMS penetrates deeper and broader in the brain than traditional TMS, there is evidence that response rates are higher than traditional TMS.
  • For more information regarding Deep TMS services at MindPath Care Centers, visit www.mindpathcare.com/TMS or call the clinic at 877-876-3783.
  • Community Psychiatry and MindPath Care Centers have combined to expand patient access to high-quality, evidence-based, outpatient mental health care across the United States.

BrainsWay to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Retrieved on: 
Tuesday, July 6, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

Dr. Randy Pardell Announced as President of the Clinical TMS Society

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Neuroscience, Medicine, Neurophysiology, Neuropsychology, Neurotechnology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, TMS, Todd M. Hutton

POUGHKEEPSIE, N.Y., June 17, 2021 /PRNewswire/ -- Dr. Randy Pardell, Medical Director of the TMS Center of Hudson Valley, has been announced President of the Clinical TMS Society.

Key Points: 
  • POUGHKEEPSIE, N.Y., June 17, 2021 /PRNewswire/ -- Dr. Randy Pardell, Medical Director of the TMS Center of Hudson Valley, has been announced President of the Clinical TMS Society.
  • Dr. Pardell's appointment was confirmed at the Clinical TMS Annual Meeting currently being held in West Palm Beach, Florida.
  • The Clinical TMS Society is an international professional association dedicated to optimizing clinical practice, awareness, and accessibility of Transcranial Magnetic Stimulation therapy.
  • Dr. Pardell has served on the Board of Directors of the Clinical TMS Society and as the Vice President 2020-21.

Greenbrook TMS Announces Results of Voting at Annual and Special Meeting of Shareholders

Retrieved on: 
Monday, June 14, 2021
Biotechnology, General Health, Mental health, Medical devices, Health, Branches of biology, Articles, Neuroscience, Corporate law, Shareholders, Neurophysiology, Neuropsychology, Treatment of depression, Board of directors, Proxy, TMS, Transcranial magnetic stimulation

Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today the results of voting at its annual and special meeting of shareholders held earlier today (the Meeting).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, announced today the results of voting at its annual and special meeting of shareholders held earlier today (the Meeting).
  • Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual and Special Meeting of Shareholders and Management Information Circular of Greenbrook dated May 7, 2021 (the Circular).
  • The total number of common shares represented by holders by proxy at the Meeting was 8,276,984, representing approximately 60.26% of Greenbrooks outstanding common shares entitled to be voted.
  • All of the nominees listed in the Management Information Circular of Greenbrook prepared in connection with the Meeting were elected as directors by a resolution passed by a majority of the shareholders represented by proxy at the Meeting, to hold office until the next annual meeting following their election or until their successors are elected or appointed.

Neuronetics Unveils New Clinical Data at Clinical TMS Society 2021 Annual Meeting

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Neuroscience, Medicine, Neurophysiology, Neuropsychology, Neurotechnology, Treatment of depression, Electrotherapy, Transcranial magnetic stimulation, TMS, Major depressive disorder, Todd M. Hutton

MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.

Key Points: 
  • MALVERN, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will present real-world clinical data as part of the Clinical TMS Society (CTMSS) Annual Meeting.
  • The CTMSS, a professional association that aims to optimize awareness and accessibility of transcranial magnetic stimulation (TMS), will hold its yearly meeting June 10-12 in West Palm Beach, Florida.
  • Its an honor and exciting to present new findings at the Clinical TMS Society Meeting, from theNeuroStar Outcomes Registry, the largest depression registry in the world, said Harold A. Sackeim,PhD, Professor of Clinical Psychology in Psychiatry and Radiology at the College of Physicians and Surgeons, Columbia University, and presenter at the Clinical TMS Society Annual Meeting.
  • Visit the Clinical TMS Societys website to learn more about the annual meeting.

BrainsWay to Present at the Raymond James Human Health Innovation Conference

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, TMS

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS.

BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate

Retrieved on: 
Monday, June 7, 2021
Branches of biology, Neuroscience, Neurotechnology, Medicine, Neurophysiology, Neuropsychology, Treatment of depression, Electrotherapy, Brainsway, Transcranial magnetic stimulation, Neurostimulation, Tel Aviv Stock Exchange

(NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:

Key Points: 
  • (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments of mental health disorders, today announced the Company will participate in the upcoming global medical conferences:
    Clinical TMS Society Annual Meeting from June 10-12.
  • The Annual Meeting of the Clinical TMS Society provides a unique opportunity to connect with TMS providers and researchers from around the world.
  • Additionally, the Company will be hosting two showcase presentations featuring novel research and the clinical utility of Deep TMS.
  • Psych Congress Elevate: Virtual Experience from June 11- 13.